Viral Vectors

Backbone of Innovation: How CDMO Vector Platforms Are Accelerating Gene Therapy Development

David Alvaro, Ph.D.

Pharma's Almanac

Platforms

Built for Speed and Scale: How CDMO Cell Line Platforms Are Reshaping Biologic Development

David Alvaro, Ph.D.

Pharma's Almanac

Changing Roles

How are Advancements in Technology Reshaping the Roles and Capabilities of CDMOs and CROs in the Drug Development Life Cycle?

Pharma's Almanac

Global Access

How Can (Bio)pharmaceutical Companies Contribute to Improving Global Access to Essential Medications?

Pharma's Almanac

Viral Vector Manufacturing

Optimizing Yields, Tech Transfer, and the Supply Chain for Viral Vector Manufacturing

Andrew Moreo; Lenore Giannunzio

Andelyn Biosciences

Gene Therapy

Changing Lives, One Patient at a Time

Andelyn Biosciences

2021 Roundup: The Year of Cell and Gene Therapy

David Alvaro, Ph.D.

Pharma's Almanac

Gene Therapy Manufacturing

Leveraging Partnerships and a Unique History to Address Supply Chain and Capacity Challenges in Gene Therapy Manufacturing

Wade Macedone; Adam Lauber

Andelyn Biosciences

Cell and Gene Therapy

Coping with a Talent Shortage and Talent War in Cell and Gene Therapy

Cyrill Kellerhals; Sarah O'Reilly

Andelyn Biosciences

Viral Vectors

Navigating Analytical Requirements for GMP Viral Vectors

Will Fountain

Andelyn Biosciences

Gene Therapy

Building a Bridge of Equivalence to Facilitate and Implement Rapid Process Changes in Gene Therapy Manufacturing

Wade Macedone; Jonathan Rush; Phillip Vermilion; Samir Acharya, Ph.D.

Andelyn Biosciences

Gene Therapy

Andelyn Biosciences: A New CDMO with Roots in Gene Therapy Research Set to Drive Key Manufacturing Advances

Wade Macedone; Mayo Pujols

Andelyn Biosciences